SynthesisJournal of lipid research2015
The rs738409 (I148M) variant of the PNPLA3 gene and cirrhosis: a meta-analysis.
Synthesis in Journal of lipid research, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 4 syntheses or guidelines pooled it, 68 citations in OpenAlex.
- Meta-Analysis: Redefining Liver Disease Risk in Heterozygous Alpha-1 Antitrypsin Deficiency.Alimentary pharmacology & therapeutics · 2026Pooled it
- Association between PNPLA3 rs738409 and susceptibility to etiology-specific liver cirrhosis: a systematic review and meta-analysis.BMC medical genomics · 2026Pooled it
- Genetic factors that affect nonalcoholic fatty liver disease: A systematic clinical review.World journal of gastroenterology · 2016Pooled it
- Definitions of Normal Liver Fat and the Association of Insulin Sensitivity with Acquired and Genetic NAFLD-A Systematic Review.International journal of molecular sciences · 2016Pooled it
- Ethnic-specific ZJU index thresholds for hepatic steatosis and fibrosis in Chinese MASLD.Frontiers in medicine · 2026Article
- Metabolic Dysfunction-Associated Steatotic Liver Disease: A Silent Driver of Cardiovascular Risk and a New Target for Intervention.International journal of molecular sciences · 2025Review
- Metabolic-dysfunction associated steatotic liver disease and atrial fibrillation: A review of pathogenesis.World journal of cardiology · 2025Review
- MAFLD: A Comprehensive Review of the Link Between Metabolic Dysfunction and Cardiovascular Risk.Hepatic medicine : evidence and research · 2025Review
- The interplay between nutrigenomics and low-carbohydrate ketogenic diets in personalized healthcare.Frontiers in nutrition · 2025Review
- Article
- Lipid droplet targeting of ABHD5 and PNPLA3 I148M is required to promote liver steatosis.bioRxiv : the preprint server for biology · 2024Article
- Epidemiology and diagnosis of metabolic dysfunction-associated fatty liver disease.Hepatology international · 2024Review
- Metabolic dysfunction-associated steatotic liver disease and cardiovascular risk: a comprehensive review.Cardiovascular diabetology · 2024Review
- Inflammatory Response in the Pathogenesis and Treatment of Hepatocellular Carcinoma: A Double-Edged Weapon.International journal of molecular sciences · 2024Review
- The fatty liver disease-causing protein PNPLA3-I148M alters lipid droplet-Golgi dynamics.Proceedings of the National Academy of Sciences of the United States of America · 2024Article
- The Intersection of Genetic Factors, Aberrant Nutrient Metabolism and Oxidative Stress in the Progression of Cardiometabolic Disease.Antioxidants (Basel, Switzerland) · 2024Review
- Current epidemiology of chronic liver disease.Gastroenterology report · 2024Review
- Non-alcoholic fatty liver disease: Role of PNPLA3 and its association with environmental chemicals.Archives of clinical toxicology · 2024Article
- Polymorphisms Associated With Metabolic Dysfunction-Associated Steatotic Liver Disease Influence the Progression of End-Stage Liver Disease.Gastro hep advances · 2024Article
- Comparison of wild-type and high-risk PNPLA3 variants in a human biomimetic liver microphysiology system for metabolic dysfunction-associated steatotic liver disease precision therapy.Frontiers in cell and developmental biology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The human patatin-like phospholipase domain-containing-3 (PNPLA3) gene rs738409 C>G polymorphism is associated with several types of liver disease. The aim of this meta-analysis was to assess the risk of cirrhosis on the basis of rs738409 allele frequency and genotype. Medline, the Cochrane Library, EMBASE, and Google Scholar were searched for prospective and retrospective studies assessing the effect of the rs738409 polymorphism on liver cirrhosis. Seven studies, involving 2,023 patients with cirrhosis, were included. The G allele was associated with a significantly increased risk of cirrhosis versus the C allele [pooled odds ratio (OR) = 1.86, 95% confidence interval (CI) = 1.64-2.12, Z = 9.55, P < 0.001]. Both the GC and GG genotypes were associated with a significantly increased risk of cirrhosis versus the CC genotype (GC vs. CC: pooled OR = 1.73, 95% CI = 1.51-1.98, Z = 7.86, P < 0.001; GG vs. CC: pooled OR = 3.41, 95% CI = 2.77-4.18, Z = 11.65, P < 0.001). There was no evidence of publication bias. Our findings suggest that patients at risk for liver cirrhosis may benefit from PNPLA3 genotyping and thus more intensive monitoring if the rs738409 C>G polymorphism is identified.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.